Lewy body dementia is the second most common neurodegenerative dementia and is pathologically characterized by α-synuclein positive cytoplasmic inclusions, with varying amounts of amyloid-β (Aβ) and hyperphosphorylated tau (tau) aggregates in addition to synaptic loss. A dysfunctional ubiquitin proteasome system (UPS), the major proteolytic pathway responsible for the clearance of short lived proteins, may be a mediating factor of disease progression and of the development of α-synuclein aggregates. In the present study, protein expression of a key component of the UPS, the RPT6 subunit of the 19S regulatory complex was determined. Furthermore, the main proteolytic-like (chymotrypsin- and PGPH-) activities have also been analyzed. The middle frontal (Brodmann, BA9), inferior parietal (BA40), and anterior cingulate (BA24) gyrus’ cortex were selected as regions of interest from Parkinson’s disease dementia (PDD, n = 31), dementia with Lewy bodies (DLB, n = 44), Alzheimer’s disease (AD, n = 16), and control (n = 24) brains. Clinical and pathological data available included the MMSE score. DLB, PDD, and AD were characterized by significant reductions of RPT6 (one-way ANOVA, p < 0.001; Bonferroni post hoc test) in prefrontal cortex and parietal cortex compared with controls. Strong associations were observed between RPT6 levels in prefrontal, parietal cortex, and anterior cingulate gyrus and cognitive impairment (p = 0.001, p = 0.001, and p = 0.008, respectively). These findings highlight the involvement of the UPS in Lewy body dementia and indicate that targeting the UPS may have the potential to slow down or reduce the progression of cognitive impairment in DLB and PDD.
McKeithIG, DicksonDW, LoweJ, EmreM, O’BrienJT, FeldmanH, CummingsJ, DudaJE, LippaC, PerryEK, AarslandD, AraiH, BallardCG, BoeveB, BurnDJ, CostaD, Del SerT, DuboisB, GalaskoD, GauthierS, GoetzCG, Gomez-TortosaE, HallidayG, HansenLA, HardyJ, IwatsuboT, KalariaRN, KauferD, KennyRA, KorczynA, KosakaK, LeeVMY, LeesA, LitvanI, LondosE, LopezOL, MinoshimaS, MizunoY, MolinaJA, Mukaetova-LadinskaEB, PasquierF, PerryRH, SchulzJB, TrojanowskiJQ, YamadaM, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium. Neurology65, 1863–1872.
2.
McKeithI, MintzerJ, AarslandD, BurnD, ChiuH, Cohen-MansfieldJ, DicksonD, DuboisB, DudaJE, FeldmanH, GauthierS, HallidayG, LawlorB, LippaC, LopezOL, MachadoJC, O’BrienJ, PlayferJ, ReidW, International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. Lancet Neurol3, 19–28.
3.
TsuboiY, DicksonDW (2005) Dementia with Lewy bodies and Parkinson’s disease with dementia: Are they different?Parkinsonism Relat Disord11 Suppl 1, S47–S51.
4.
LippaCF, OzawaK, MannDM, IshiiK, SmithTW, ArawakaS, MoriH (1999) Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol56, 1111–1118.
5.
BallardC, PiggottM, JohnsonM, CairnsN, PerryR, McKeithI, JarosE, O’BrienJ, HolmesC, PerryE (2000) Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol48, 868–876.
6.
PerryEK, MarshallE, ThompsonP, McKeithIG, CollertonD, FairbairnAF, FerrierIN, IrvingD, PerryRH (1993) Monoaminergic activities in Lewy body dementia: Relation to hallucinosis and extrapyramidal features. J Neural Transm Park Dis Dement Sect6, 167–177.
7.
ZiabrevaI, BallardCG, AarslandD, LarsenJP, McKeithIG, PerryRH, PerryEK (2006) Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. Neurobiol Aging27, 433–438.
8.
EmreM, AarslandD, AlbaneseA, ByrneEJ, DeuschlG, De DeynPP, DurifF, KulisevskyJ, van LaarT, LeesA, PoeweW, RobillardA, RosaMM, WoltersE, QuargP, TekinS, LaneR (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med351, 2509–2518.
9.
McKeithIG, GraceJB, WalkerZ, ByrneEJ, WilkinsonD, StevensT, PerryEK (2000) Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial. Int J Geriatr Psychiatry15, 387–392.
10.
AarslandD, BallardC, WalkerZ, BostromF, AlvesG, KossakowskiK, LeroiI, Pozo-RodriguezF, MinthonL, LondosE (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurol8, 613–618.
11.
BennettMC, BishopJF, LengY, ChockPB, ChaseTN, MouradianMM (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem274, 33855–33858.
12.
BaumeisterW, WalzJ, ZühlF, SeemüllerE (1998) The proteasome: Paradigm of a self-compartmentalizing protease. Cell92, 367–380.
OrlowskiM, CardozoC, MichaudC (1993) Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry32, 1563–1572.
15.
TaiHC, SchumanEM (2008) Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci9, 826–838.
16.
BraunBC, GlickmanM, KraftR, DahlmannB, KloetzelPM, FinleyD, SchmidtM (1999) The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol1, 221–226.
17.
LamYA, LawsonTG, VelayuthamM, ZweierJL, PickartCM (2002) A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature416, 763–767.
18.
DennissenFJ, KholodN, van LeeuwenFW (2012) The ubiquitin proteasome system in neurodegenerative diseases: Culprit, accomplice or victim?Prog Neurobiol96, 190–207.
19.
PaulS (2008) Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: Therapeutic approaches. Bioessays30, 1172–1184.
20.
Alves-RodriguesA, GregoriL, Figueiredo-PereiraME (1998) Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci21, 516–520.
21.
McNaughtKS, BelizaireR, IsacsonO, JennerP, OlanowCW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol179, 38–46.
22.
MacInnesN, IravaniMM, PerryE, PiggottM, PerryR, JennerP, BallardC (2008) Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm115, 869–878.
23.
Figueiredo-PereiraME, BergKA, WilkS (1994) A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J Neurochem63, 1578–1581.
24.
Dyllick-BrenzingerM, D’SouzaCA, DahlmannB, KloetzelPM, TandonA (2010) Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue. Neurotox Res17, 215–227.
SnyderH, MensahK, TheislerC, LeeJ, MatouschekA, WolozinB (2003) Aggregated and monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. J Biol Chem278, 11753–11759.
27.
FusterJM (2001) The prefrontal cortex–an update: Time is of the essence. Neuron30, 319–333.
28.
AlafuzoffI, IncePG, ArzbergerT, Al-SarrajS, BellJ, BodiI, BogdanovicN, BugianiO, FerrerI, GelpiE, GentlemanS, GiacconeG, IronsideJW, KavantzasN, KingA, KorkolopoulouP, KovacsGG, MeyronetD, MonoranuC, ParchiP, ParkkinenL, PatsourisE, RoggendorfW, RozemullerA, Stadelmann-NesslerC, StreichenbergerN, ThalDR, KretzschmarH (2009) Staging/typing of Lewy body related alpha-synuclein pathology: A study of the BrainNet Europe Consortium. Acta Neuropathol117, 635–652.
29.
AlafuzoffI, ArzbergerT, Al-SarrajS, BodiI, BogdanovicN, BraakH, BugianiO, Del-TrediciK, FerrerI, GelpiE, GiacconeG, GraeberMB, InceP, KamphorstW, KingA, KorkolopoulouP, KovacsGG, LarionovS, MeyronetD, MonoranuC, ParchiP, PatsourisE, RoggendorfW, SeilheanD, TagliaviniF, StadelmannC, StreichenbergerN, ThalDR, WhartonSB, KretzschmarH (2008) Staging of neurofibrillary pathology in Alzheimer’s disease: A study of the BrainNet Europe Consortium. Brain Pathol18, 484–496.
30.
BraakH, AlafuzoffI, ArzbergerT, KretzschmarH, Del TrediciK (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffinsections and immunocytochemistry. Acta Neuropathol112, 389–404.
31.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, VanbelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
32.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
33.
ThalDR, RubU, OrantesM, BraakH (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology58, 1791–1800.
34.
FolsteinMF, FolsteinSE, McHughPR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
35.
WhitfieldDR, VallortigaraJ, AlghamdiA, HowlettD, HortobagyiT, JohnsonM, AttemsJ, NewhouseS, BallardC, ThomasAJ, O’BrienJT, AarslandD, FrancisPT (2014) Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer’s disease: Association with cognitive impairment. Neurobiol Aging35, 2836–2844.
36.
ZengBY, MedhurstAD, JacksonM, RoseS, JennerP (2005) Proteasomal activity in brain differs between species, and brain regions and changes with age. Mech Ageing Dev126, 760–766.
37.
WhitfieldDR, VallortigaraJ, AlghamdiA, HortobagyiT, BallardC, ThomasAJ, O’BrienJT, AarslandD, FrancisPT (2015) Depression and synaptic zinc regulation in Alzheimer disease, dementia with Lewy bodies, and Parkinson disease dementia. Am J Geriatr Psychiatry23, 141–148.
38.
MarquesAJ, PalanimuruganR, MatiasAC, RamosPC, DohmenRJ (2009) Catalytic mechanism and assembly of the proteasome. Chem Rev109, 1509–1536.
39.
StricklandE, HakalaK, ThomasPJ, DeMartinoGN (2000) Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. J Biol Chem275, 5565–5572.
40.
LiuB, ShiQQ, MaSP, FengN, LiJ, WangL, WangXL (2008) Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice. Biochem Biophys Res Commun376, 277–282.
41.
WillsJ, JonesJ, HaggertyT, DukaV, JoyceJN, SidhuA (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol225, 210–218.
42.
BedfordL, HayD, DevoyA, PaineS, PoweDG, SethR, GrayT, TophamI, FoneK, RezvaniN, MeeM, SoaneT, LayfieldR, SheppardPW, EbendalT, UsoskinD, LoweJ, MayerRJ (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci28, 8189–8198.
43.
YangW, ChenLN, DingYM, ZhuangXX, KangUJ (2007) Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum Mol Genet16, 2900–2910.
44.
ZengBY, IravaniMM, LinST, IrifuneM, KuoppamakiM, Al-BarghouthyG, SmithL, JacksonMJ, RoseS, MedhurstAD, JennerP (2006) MPTP treatment of commonmarmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur J Neurosci23, 1766–1774.
45.
SunXM, ButterworthM, MacFarlaneM, DubielW, CiechanoverA, CohenGM (2004) Caspase activation inhibits proteasome, function during apoptosis. Mol Cell14, 81–93.
46.
SatohK, SasajimaH, NyoumuraK, YokosawaK, SawadaH (2001) Assembly of the 26S proteasome is regulated by phosphorylation of the p45/Rpt6 ATPase subunit. Biochemistry40, 314–319.
47.
EmmanouilidouE, StefanisL, VekrellisK (2010) Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging31, 953–968.
48.
LiuCW, GiassonBI, LewisKA, LeeVM, DemartinoGN, ThomasPJ (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson disease. J Biol Chem280, 22670–22678.
49.
ZhangNY, TangZ, LiuCW (2008) alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: Understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J Biol Chem283, 20288–20298.
50.
LansburyPT, LashuelHA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature443, 774–779.
51.
McNaughtKS, MytilineouC, JnoBaptisteR, YabutJ, ShashidharanP, JennerP, OlanowCW (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem81, 301–306.
52.
GieseKP, FedorovNB, FilipkowskiRK, SilvaAJ (1998) Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science279, 870–873.
53.
MiyamotoE (2006) Molecular mechanism of neuronal plasticity: Induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol Sci100, 433–442.
54.
JaromeTJ, HelmstetterFJ (2013) The ubiquitin-proteasome system as a critical regulator of synaptic plasticity and long-term memory formation. Neurobiol Learn Mem105, 107–116.
55.
JaromeTJ, KwapisJL, RuenzelWL, HelmstetterFJ (2013) CaMKII, but not protein kinase A, regulates Rpt6 phosphorylation and proteasome activity during the formation of long-term memories. Front Behav Neurosci7, 115.
56.
BingolB, WangCF, ArnottD, ChengD, PengJ, ShengM (2010) Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell140, 567–578.
57.
BingolB, SchumanEM (2006) Activity-dependent dynamics and sequestration of proteasomes in dendritic spines. Nature441, 1144–1148.
58.
ChengBX, MartinezAA, MoradoJ, ScofieldV, RobertsJL, MaffiSK (2013) Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway. Neurochem Int62, 31–42.
59.
MatilainenO, ArpalahtiL, RantanenV, HautaniemiS, HolmbergCI (2013) Insulin/IGF-1 signaling regulates proteasome activity through the deubiquitinating enzyme UBH-4. Cell Rep3, 1980–1995.
60.
SaezI, VilchezD (2014) The mechanistic links between proteasome activity, aging and agerelated diseases. Curr Genomics15, 38–51.
61.
TongM, DongM, de la MonteSM (2009) Brain insulin-like growth factor and neurotrophin resistance in Parkinson’sdisease and dementia with Lewy bodies: Potential role of manganese neurotoxicity. J Alzheimers Dis16, 585–599.
